News
-
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Patients May See Improved Outcomes with Ravulizumab
The findings showed that patients treated with ravulizumab demonstrated better adherence and persistence compared to those on other complement inhibitors. The ADVANTAGE study, a retrospective longitudinal analysis, included data from…
Read More » -
JUST RELEASED | 5th Edition of TIF’s Guidelines for the Management of Transfusion Dependent β-Thalassaemia
This edition stands as a seminal resource that provides critical guidance and recommendations to healthcare professionals across various specialties, researchers and all stakeholders involved in the care of individuals affected…
Read More » -
TIF AI KNOWLEDGE BOT | Your Go-To Source for Thalassaemia Information
In the world of healthcare, staying informed is key. That is why the TIF AI Knowledge Bot is here to revolutionize how you access thalassaemia information. Designed with patients, caregivers,…
Read More » -
EDUCATIONAL WEBINAR ON HEART COMPLICATIONS IN HAEMOGLOBINOPATHIES | 30 January 2025
📌 Webinar Title: Management of Thalassaemia: Heart Complications in Haemoglobinopathies 📌 Date & Time: Thursday, 30 January 2025, 13:00 New York / 14:00 Rio de Janeiro / 20:00 Athens …
Read More » -
HEALTH TECHNOLOGY ASSESSMENT | EU Implements New Rules to Offer Quicker Access to Advanced Medicines
The new rules establish an EU-wide framework for assessing health technologies by promoting collaboration and coordination among EU Member States. The goal is to help national authorities make more timely…
Read More » -
TIF CARE | A New Era in Healthcare Collaboration
Mark your Calendars for the TIF CARE Launch Currently, TIF Care is in its pilot phase and the official launch is scheduled for April 2025. We will continue to…
Read More » -
TIF READINESS ASSESSMENT TOOL | Is Your Country Ready for Advanced Thalassaemia Therapies?
In an era where medical advancements are progressing at an unprecedented rate, ensuring that these breakthroughs are accessible and appropriately integrated into national healthcare systems is a paramount challenge. This…
Read More » -
WEBINAR | New Advances in the Prevention of Thalassaemia: Potential for High-Prevalence Regions
📌 Webinar Title: New Advances in the Prevention of Thalassaemia: Potential for High-Prevalence Regions 📌 Date & Time: Tuesday, 21 January 2025 | 14:30-16:00 Athens Time, 19:30-21:00 Kuala Lumpur Time Webinar…
Read More » -
NEW FACTSHEET | The Advanced Therapy Medicinal Products (ATMPs) Labyrinth
Featuring comprehensive information on: The Regulation of ATMPs in the EU List of gene-based products approved by the EMA/FDA Challenges in Patient Access to ATMPs Key Recommendations for Improving Patient…
Read More » -
POSITION PAPER | The Views of TIF on Advanced Therapy Medicinal Products (ATMPs)
The Thalassaemia International Federation (TIF) is pleased to share its newly published Position Paper, titled “Advanced Therapy Medicinal Products (ATMPs).” This comprehensive document delves into the challenges eligible patients face…
Read More »